MX2022002466A - Iniciadores y constructo de car t del complejo de maduración de células b. - Google Patents

Iniciadores y constructo de car t del complejo de maduración de células b.

Info

Publication number
MX2022002466A
MX2022002466A MX2022002466A MX2022002466A MX2022002466A MX 2022002466 A MX2022002466 A MX 2022002466A MX 2022002466 A MX2022002466 A MX 2022002466A MX 2022002466 A MX2022002466 A MX 2022002466A MX 2022002466 A MX2022002466 A MX 2022002466A
Authority
MX
Mexico
Prior art keywords
cell maturation
car
primers
construct
kits
Prior art date
Application number
MX2022002466A
Other languages
English (en)
Inventor
Rebecca George
Dee Shen
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of MX2022002466A publication Critical patent/MX2022002466A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2545/00—Reactions characterised by their quantitative nature
    • C12Q2545/10—Reactions characterised by their quantitative nature the purpose being quantitative analysis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2563/00—Nucleic acid detection characterized by the use of physical, structural and functional properties
    • C12Q2563/107—Nucleic acid detection characterized by the use of physical, structural and functional properties fluorescence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención proporciona conjuntos de sondas e iniciadores, y métodos y kits relacionados, para generar células T con receptor de antígeno quimérico (CAR) del antígeno de maduración de células B. La invención también proporciona conjuntos de sondas e iniciadores, y métodos y kits relacionados, para realizar reacciones en cadena de la polimerasa cuantitativas para cuantificar la integración transgénica del CAR del antígeno de maduración de células B en un producto farmacológico de CAR T.
MX2022002466A 2019-08-30 2020-08-28 Iniciadores y constructo de car t del complejo de maduración de células b. MX2022002466A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962894663P 2019-08-30 2019-08-30
PCT/IB2020/058070 WO2021038524A1 (en) 2019-08-30 2020-08-28 B-cell maturation complex car t construct and primers

Publications (1)

Publication Number Publication Date
MX2022002466A true MX2022002466A (es) 2022-06-02

Family

ID=72356220

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022002466A MX2022002466A (es) 2019-08-30 2020-08-28 Iniciadores y constructo de car t del complejo de maduración de células b.

Country Status (12)

Country Link
US (1) US20210164045A1 (es)
EP (1) EP4022091A1 (es)
JP (1) JP2022546978A (es)
KR (1) KR20220051002A (es)
CN (1) CN114341365A (es)
AU (1) AU2020339086A1 (es)
BR (1) BR112022003648A2 (es)
CA (1) CA3152237A1 (es)
IL (1) IL290926A (es)
JO (1) JOP20220049A1 (es)
MX (1) MX2022002466A (es)
WO (1) WO2021038524A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023516789A (ja) * 2020-03-09 2023-04-20 ヤンセン バイオテツク，インコーポレーテツド 組換えベクター核酸の統合を定量化するための組成物及び方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2909099B1 (fr) * 2006-11-24 2012-10-19 Univ Aix Marseille Ii Methode de diagnostic et de suivi d'une vaginose bacterienne par quantification moleculaire.
US20110251091A1 (en) * 2008-09-12 2011-10-13 Cornell University Thyroid tumors identified
US10301370B2 (en) * 2014-05-02 2019-05-28 The Trustees Of The University Of Pennsylvania Compositions and methods of chimeric autoantibody receptor T cells
CN107921148A (zh) * 2015-05-08 2018-04-17 哈佛学院校长同事会 通用供体干细胞和相关方法
CN105384825B (zh) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
CN105837693A (zh) * 2016-05-30 2016-08-10 李斯文 一种基于bcma的抗原嵌合受体及其制备方法和应用
CN109971836A (zh) * 2017-12-28 2019-07-05 上海细胞治疗研究院 双重荧光定量pcr测定car拷贝数的方法和试剂盒
CN109722472A (zh) * 2019-02-28 2019-05-07 上海邦耀生物科技有限公司 检测嵌合抗原受体基因的通用型pcr引物组合及应用
CN109722468A (zh) * 2019-02-28 2019-05-07 上海邦耀生物科技有限公司 检测bcma嵌合抗原受体基因的pcr引物组合及应用

Also Published As

Publication number Publication date
US20210164045A1 (en) 2021-06-03
KR20220051002A (ko) 2022-04-25
AU2020339086A1 (en) 2022-04-14
CN114341365A (zh) 2022-04-12
CA3152237A1 (en) 2021-03-04
EP4022091A1 (en) 2022-07-06
JOP20220049A1 (ar) 2023-01-30
IL290926A (en) 2022-04-01
JP2022546978A (ja) 2022-11-10
BR112022003648A2 (pt) 2022-05-24
WO2021038524A1 (en) 2021-03-04

Similar Documents

Publication Publication Date Title
WO2018132635A8 (en) Methods for analyzing t cell receptors and b cell receptors
MX2022005152A (es) Uso de receptores de antigenos quimericos anti-bcma.
PH12021550419A1 (en) Methods of making chimeric antigen receptor-expressing cells
EP3824075A4 (en) T LYMPHOCYTES CHEMERA ANTIGEN RECEPTORS DERIVED FROM PLURIPOTEN STEM CELLS OBTAINED BY GENETIC ENGINEERING
PE20211887A1 (es) Receptor antigenico quimerico (car) que comprende un dominio de union a antigenos, el cual se une selectivamente a la region constante del tcr beta 1 (trbc1) o trbc2 de celulas t
MX2022009625A (es) Receptores de antigenos quimericos condicionalmente activos para celulas t modificadas.
BR112022010206A2 (pt) Receptores de antígeno quiméricos e usos dos mesmos
WO2016094304A3 (en) Bcma chimeric antigen receptors
MX2021008652A (es) Receptores de antígenos quiméricos de gprc5d y células que los expresan.
EA201992469A1 (ru) Антигенспецифические иммунные эффекторные клетки
BR112017014551A2 (pt) ?anticorpo, construção de ácido nucleico, vetor de expressão, célula hospedeira, composição, métodos para tratamento de uma doença, para produção de um anticorpo biespecífico e para detecção da possível ocorrência de reticulação entre células com expressão de cd3 e cd20 em uma amostra derivada de um paciente, uso de um anticorpo biespecífico, e, kit?
AU2016245958A8 (en) CD20 therapies, CD22 therapies, and combination therapies with a CD19 Chimeric Antigen Receptor (CAR) - expressing cell
WO2015081229A3 (en) Selective amplification of nucleic acid sequences
WO2018236870A3 (en) METHODS AND COMPOSITIONS FOR TARGETING CANCER CELLS WITH A CHIMERIC ANTIGENIC RECEPTOR
MX2017002785A (es) Sintesis de acido desoxirribonucleico (adn).
MX2017002875A (es) Metodos para tratar una enfermedad o trastorno usando formulaciones orales de analogos de citidina en combinacion con un anticuerpo monoclonal anti-pd1 o anti-pdl1.
WO2019232409A9 (en) Methods for genome editing and activation of cells
MX2020013017A (es) Materiales y metodos para tratar cancer.
MX2019000641A (es) Composiciones de mucina1-receptor de antigeno quimerico y metodos para su uso.
MX2018012868A (es) Composiciones y metodos para generar anticuerpos basado en el uso de loci potenciadores de expresion.
EP3947471A4 (en) TN-MUC1 CHIMERIC ANTIGEN RECEPTOR (CAR) T-LYMPHOCYTE THERAPY
JOP20220049A1 (ar) مشرعات وتركيبات car t خاصة بمركب نضج الخلايا البائية
SG11201908659RA (en) Chimeric antigen receptor
BR112021019411A2 (pt) Métodos para a produção de células car-nk e uso das mesmas
NZ728981A (en) Anti-ceramide antibodies